Literature DB >> 11823268

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Jan Volavka1, Pal Czobor, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos, Jeffrey A Lieberman.   

Abstract

OBJECTIVE: The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder.
METHOD: In a double-blind trial, 157 inpatients with a history of suboptimal treatment response were randomly assigned to treatment with clozapine, olanzapine, risperidone, or haloperidol for 14 weeks (an 8-week escalation and fixed-dose period followed by a 6-week variable-dose period).
RESULTS: Clozapine, risperidone, and olanzapine (but not haloperidol) resulted in statistically significant improvements in total score on the Positive and Negative Syndrome Scale. Improvements seen in total and negative symptom scores with clozapine and olanzapine were superior to haloperidol. The atypical drugs, particularly olanzapine and clozapine, were associated with weight gain.
CONCLUSIONS: The effects of atypical antipsychotics in this population were statistically significant but clinically modest. The overall pattern of results suggests that clozapine and olanzapine have similar general antipsychotic efficacy and that risperidone may be somewhat less effective. Clozapine was the most effective treatment for negative symptoms. However, the differences among treatments were small.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823268     DOI: 10.1176/appi.ajp.159.2.255

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  81 in total

Review 1.  Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders.

Authors:  Julie Pongrac; Frank A Middleton; David A Lewis; Pat Levitt; Károly Mirnics
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity.

Authors:  Cyrille Sur; Pierre J Mallorga; Marion Wittmann; Marlene A Jacobson; Danette Pascarella; Jacinta B Williams; Philip E Brandish; Douglas J Pettibone; Edward M Scolnick; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

Review 3.  Dose response and atypical antipsychotics in schizophrenia.

Authors:  Bruce J Kinon; Jonna Ahl; Virginia L Stauffer; Angela L Hill; Peter F Buckley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 4.  Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.

Authors:  Louis S Matza; Timothy M Baker; Dennis A Revicki
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.

Authors:  Jonathan Rabinowitz; Stephen Z Levine; Orna Barkai; Ori Davidov
Journal:  Schizophr Bull       Date:  2008-02-26       Impact factor: 9.306

6.  Switch from risperidone to perospirone in patients with chronic schizophrenia.

Authors:  Kazuyuki Fujita; Toshihiko Fukuchi; Shoji Yuasa; Eriko Inada; Yoko Tarao; Kousuke Kanemoto
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

7.  Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.

Authors:  Taro Kunitomi; Masayuki Hashiguchi; Mayumi Mochizuki
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

8.  Investigation into effects of antipsychotics on ectonucleotidase and adenosine deaminase in zebrafish brain.

Authors:  Kelly Juliana Seibt; Renata da Luz Oliveira; Mauricio Reis Bogo; Mario Roberto Senger; Carla Denise Bonan
Journal:  Fish Physiol Biochem       Date:  2015-07-09       Impact factor: 2.794

9.  Dropout rates with olanzapine or risperidone: a multi-centre observational study.

Authors:  F Pelagotti; B Santarlasci; F Vacca; S Trippoli; A Messori
Journal:  Eur J Clin Pharmacol       Date:  2003-12-19       Impact factor: 2.953

Review 10.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.